We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Stefan Hümmer, main researcher Translational Molecular Pathology (VHIR)
Abstract: Therapy resistance remains a main cause of therapeutic failure in cancer treatment. Immunotherapy has opened a new avenue in oncology, but is only effective in a small fraction of patients. Therapy resistance and immune evasion critically rely on the activation of stress response pathways. Those pathways activate the kinases MNK1/2 which uniquely regulate eIF4E. Phosphorylation of eIF4E is associated worse prognosis in several tumors and targeting MNKs has evolved as strategy in oncology.
CV summary: Stefan Hümmer obtained his PhD in Biology in 1999 from the Ludwig Maximilian University in Munich. During his scientific carrier, he was working at the Max-Planck Institute in Munich (PhD), the Biozentrum in Basel and the PRBB in Barcelona (post-doctoral fellow). After extending his scientific horizon on the work with genetic model organisms, he returned to his longstanding interest in small molecule inhibitors, either as tools to study basic cellular functions, or as potential drug targets. In this regard, his research has resulted in several research publications as first and/or corresponding author and four patent applications. In his function as senior researcher, he is responsible for the research laboratory “Translational Molecular Pathology” of Santiago Ramon y Cajal at VHIR since 2017. He is member of the research network in oncology (CIBER, ICSIII) and is currently hired as postdoctoral researcher for the project MNKImmunoOnco through the research program of “Plan Complementario (IBEC)”.
Host: Dr. Santiago Ramón y Cajal, head of group Translational Molecular Pathology (VHIR)
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.